β-Nicotinamide mononucleotide-d4

β-Nicotinamide mononucleotide-d4

• UNSPSC Description: β-Nicotinamide mononucleotide-d4 is the deuterium labeled β-Nicotinamide mononucleotide. β-nicotinamide mononucleotide (β-NM) is a product of the nicotinamide phosphoribosyltransferase (NAMPT) reaction and a key NAD+ intermediate. The pharmacological activities of β-nicotinamide mononucleotide include its role in cellular biochemical functions, cardioprotection, diabetes, Alzheimer's disease, and complications associated with obesity[1].
• Target Antigen: Endogenous Metabolite
• Type: Isotope-Labeled Compounds
• Related Pathways: Metabolic Enzyme/Protease
• Field of Research: Cancer; Neurological Disease
• Purity: 99.55
• Solubility: H2O : 83.33 mg/mL (ultrasonic;warming)
• Smiles: O[C@H]1[C@@H](O)[C@H]([N+]2=C([2H])C([2H])=C([2H])C(C(N)=O)=C2[2H])O[C@@H]1COP(O)([O-])=O
• Molecular Weight: 338.24
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Poddar SK, et al. Nicotinamide Mononucleotide: Exploration of Diverse Therapeutic Applications of a Potential Molecule. Biomolecules. 2019;9(1):34. Published 2019 Jan 21.|[3]Lv H, et al. NAD+ Metabolism Maintains Inducible PD-L1 Expression to Drive Tumor Immune Evasion [published online ahead of print, 2020 Nov 3]. Cell Metab. 2020;S1550-4131(20)30554-4.|[4]Li J, et al. p53 prevents doxorubicin cardiotoxicity independently of its prototypical tumor suppressor activities. Proc Natl Acad Sci U S A. 2019;116(39):19626-19634.|[5]Yoshino J, et al Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 2011;14(4):528-536.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C, 3 years (Powder)
• Clinical Information: No Development Reported